Moscow, 20 January 2009 – JSC Pharmstandard (LSE: PHST LI, RTS: PHST RU) announces European Union Good Manufacturing Practice (EU GMP) certifications obtainment for 6 production lines of JSC «Pharmstandard-Leksredstva». Latvian State Medicines Agency during its prior inspection confirmed that products are consistently produced and controlled to the quality standards appropriate to their intended use according to GMP guidelines.

GMP certificates obtainment is the result of company’s continuous work (started in 2005) for the product lines certification. At present, 6 production lines (65% of the total production capacity) of JSC «Pharmstandard-Leksredstva» meet GMP requirements. In 2008 the company produced 160 million packs of tablets, capsules, sachets, sprays, syrups and suspensions on the certified lines.

Igor Krylov, CEO of JSC “Pharmstandard” commented:

 «EU GMP certifications obtainment for JSC «Pharmstandard-Leksredstva» is the result of longstanding, labour-intensive efforts of our employees, capital expenditures in new production lines construction and launching. JSC «Pharmstandard-Leksredstva» is the first Russian pharmaceutical plant included in EudraGMP database».

For additional information about EU GMP, and EudraGMP please use the following link:

http://www.emea.europa.eu/Inspections/GMPhome.html

Contacts:

OJSC Pharmstandard
Anton Golubok
Tel: +7 495 970 0030 ext 2029
E-mail: ir@pharmstd.ru
www.pharmstd.ru

***

Pharmstandard is the leading domestic pharmaceutical company in Russia and the second largest pharmaceutical company operating in Russia overall, by sales value. Pharmstandard is a leader of the biggest commercial segment of the Russian pharmaceutical segment. The Company develops, manufactures, markets and sells original and generic pharmaceutical products in various formulations, primarily in Russia.  Pharmstandard’s product portfolio includes market-leading brands (7 brands among top-15 best selling domestic brands in Russia), such as Arbidol® (antiviral for systemic use), Pentalgin® (analgesics), Terpincod® (cough and cold), Complivit® (vitamins), Phosphogliv® (hepatic protector), Flucostat® (antifungal), Amixin® (immunomodulating) . In 2007, Arbidol® was the largest selling pharmaceutical product at the commercial segment of the Russian pharmaceutical market, according to pharmacy audit data by Pharmexpert. Pentalgin® has been granted “BRAND #1 IN RUSSIA” award for 2008 in analgesics category.  

Pharmstandard operates five manufacturing facilities in Russia and, with a production capacity of 1.3 billion packs per year, has one of the largest production capacities among domestic pharmaceutical companies in Russia. The Company has invested approximately RUR 3 billion in capital investments in its manufacturing facilities since the start of 2004. Pharmstandard’s flexible production capacity distinguishes it from the competitors by allowing quickly and efficiently adjust production, based on input from its distributors and sales force.

In addition to its pharmaceutical business, the Company also develops, manufactures, markets and sells medical equipment, such as sterilizing and distilling machines, and disposable medical products.

www.pharmstd.ru